|1.||Donnelly, Ryan F: 1 article (09/2012)|
|2.||Fallows, Steven J: 1 article (09/2012)|
|3.||Garland, Martin J: 1 article (09/2012)|
|4.||Cassidy, Corona M: 1 article (09/2012)|
|5.||Tunney, Michael M: 1 article (09/2012)|
|6.||Singh, Thakur Raghu Raj: 1 article (09/2012)|
|7.||Woolfson, A David: 1 article (01/2004)|
|8.||Jones, David S: 1 article (01/2004)|
|9.||Lawlor, Michelle S: 1 article (01/2004)|
|1.||Periodontal Diseases (Periodontal Disease)
01/01/2004 - "Based on the drug release, rheological and textural properties, it is suggested that the formulation containing 15% w/w PMVE-MA, 6% w/w PVP and tetracycline hydrochloride (5% w/w) may be useful for the treatment of periodontal disease."
01/01/2004 - "This study described the drug release, rheological (dynamic and flow) and textural/mechanical properties of a series of formulations composed of 15% w/w polymethylvinylether-co-maleic anhydride (PMVE-MA), 0-9% w/w polyvinylpyrrolidone (PVP) and containing 1-5% w/w tetracycline hydrochloride, designed for the treatment of periodontal disease. "
|2.||Wounds and Injuries (Trauma)
|5.||Thymidine Monophosphate (TMP)